The global Mammalian Biologics CDMO Services market size is predicted to grow from US$ 4726 million in 2025 to US$ 8250 million in 2031; it is expected to grow at a CAGR of 9.7% from 2025 to 2031.

Mammalian Biologics CDMO (Contract Development and Manufacturing Organization) Services refer to the specialized services provided by companies that offer development, manufacturing, and production support for biologic drugs derived from mammalian cell cultures. These services are critical for the production of biologics, which are complex, biologically-derived therapeutic products, including monoclonal antibodies (mAbs), vaccines, therapeutic proteins, and cell and gene therapies.

United States market for Mammalian Biologics CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Mammalian Biologics CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Mammalian Biologics CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Mammalian Biologics CDMO Services players cover Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Mammalian Biologics CDMO Services Industry Forecast” looks at past sales and reviews total world Mammalian Biologics CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Mammalian Biologics CDMO Services sales for 2025 through 2031. With Mammalian Biologics CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mammalian Biologics CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Mammalian Biologics CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Mammalian Biologics CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mammalian Biologics CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mammalian Biologics CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mammalian Biologics CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Mammalian Biologics CDMO Services market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other

Segmentation by Application:

    SMBs
    Large Companies

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Lonza
    Catalent
    Samsung Biologics
    FUJIFILM Diosynth Biotechnologies
    Boehringer Ingelheim
    WuXi AppTech
    Recipharm
    Thermo Fisher Scientific
    AGC Biologics
    Rentschler Biopharma
    KBI Biopharma
    Siegfried
    Aenova Group
    GenScript
    ProBioGen
    Northway Biotech
    3P Biopharmaceuticals